Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.

Authors

Simone Kayser

University Children's Hospital, Tübingen, Germany

Simone Kayser , Vanya Icheva , Stefan Stevanovic , Nikolai Siebert , Judith Feucht , Holger N. Lode , Rupert Handgretinger , Tobias Feuchtinger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Citation

J Clin Oncol 33, 2015 (suppl; abstr 3029)

DOI

10.1200/jco.2015.33.15_suppl.3029

Abstract #

3029

Poster Bd #

355

Abstract Disclosures

FEATURED

Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.

Authors

Simone Kayser

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma.

Poster

Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.

Poster

ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].

Poster

Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).